Author(s):
Sandip S. Kshirsager, Dr. Siraj N. Shaikh, Narendra B. Patil, Ketan B. Patil
Email(s):
sandipkshirsagar53@gmail.com
DOI:
10.5958/2231-5659.2020.00019.3 
Address:
Sandip S. Kshirsager1*, Dr. Siraj N. Shaikh1, Narendra B. Patil2, Ketan B. Patil2
1Department of Pharmaceutics, Ali Allana College of Pharmacy, Akkalkuwa, Maharashtra
2Department of Pharmacology, Ahinsa Institute of Pharmacy, Dondaicha, Dist-Dhule, Maharashtra
*Corresponding Author
Published In:
Volume - 10,
Issue - 2,
Year - 2020
ABSTRACT:
Cancer is leading cause of death worldwide, accounting for an estimated 9.6 million deaths in 2018.Breast cancer 2.09 million death in 2018. Approximately 70% of deaths from cancer occurs in low- and middle-income countries. Human epidermal growth factor receptor (HER) 2 is overexpressed in 20 -25% of breast cancer and has historically been poor prognostics marker. Niratinib maleate is an anti breast cancer drug .it is crystalline form and chemically (2E)-N-[4-[[3-chloro-4-[(pyridin-2-yl) methoxy] phenyl] amino]-3-cyano-7-ethoxyquinolin-6-yl]-4-(dimethylamino) but-2-enamide maleate. It an oral, irreversible pan-Erb B receptor tyrosine kinase inhibitor and it can effectively inhibit the activity of Erb B1, ErbB2 tyrosine kinase.
Cite this article:
Sandip S. Kshirsager, Dr. Siraj N. Shaikh, Narendra B. Patil, Ketan B. Patil. Novel Molecule of Protein Tyrosine Kinase Enzyme Inhibitor in Treatment of Breast Cancer: Neratinib Maleate. Asian J. Res. Pharm. Sci. 2020; 10(2):100-102. doi: 10.5958/2231-5659.2020.00019.3
Cite(Electronic):
Sandip S. Kshirsager, Dr. Siraj N. Shaikh, Narendra B. Patil, Ketan B. Patil. Novel Molecule of Protein Tyrosine Kinase Enzyme Inhibitor in Treatment of Breast Cancer: Neratinib Maleate. Asian J. Res. Pharm. Sci. 2020; 10(2):100-102. doi: 10.5958/2231-5659.2020.00019.3 Available on: https://ajpsonline.com/AbstractView.aspx?PID=2020-10-2-8